Augmedix, a medical documentation company, is expected to conduct a public offering of its stock. The deal is contingent upon the approval of its application for listing on the Nasdaq.
The stock is currently traded on the Over-the-Counter Market under the ticker symbol "AUGX," and if approved, it will trade on the Nasdaq under the same symbol.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.31 |
|---|---|
| 52-week range | $0.73 - $6.25 |
| 50-day moving average | $1.75 |
| 200-day moving average | $3.30 |
| Wall St. target price | $3.52 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.47 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.31 from 2024-09-06
| 1 week (2024-09-03) | 2.31 |
|---|---|
| 1 month (2024-08-09) | 1.76% |
| 3 months (2024-06-10) | 171.76% |
| 6 months (2024-03-08) | -37.23% |
| 1 year (2023-09-08) | -53.05% |
|---|---|
| 2 years (2022-09-09) | 11.06% |
| 3 years (2021-09-10) | 5 |
| 5 years (2019-09-06) | N/A |
| Revenue TTM | $51.6 million |
|---|---|
| Gross profit TTM | $14 million |
| Return on assets TTM | -30.61% |
| Return on equity TTM | -329.78% |
| Profit margin | -46.23% |
| Book value | $0.21 |
| Market Capitalization | $114.7 million |
TTM: trailing 12 months
We're not expecting Augmedix to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Augmedix's shares have ranged in value from as little as $0.73 up to $6.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Augmedix's is -0.189. This would suggest that Augmedix's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Augmedix has bucked the trend.
To put Augmedix's beta into context you can compare it against those of similar companies.
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was formerly known as Malo Holdings Corporation and changed its name to Augmedix, Inc. in October 2020.
Use this calculator to quickly see potential outcomes of your options trades.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.